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specific research questions. Results: We identified 327 national or regional general 
oncology registries. Almost each country has databases collecting information on 
diagnosis and survival data, but databases collecting information on treatment and 
response to treatment are rare. Interviews revealed that medical records typically 
collect detailed information on diagnosis, treatment and response, although specific 
details vary per country. ConClusions: The method tested represents a practical 
guide for identifying and assessing available RWE-sources. Patient-registries con-
taining detailed data are good sources for RWE gathering, but in countries without 
such registries, data collection from clinical practice is still a feasible alternative 
for RWE collection
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objeCtives: To understand the early lifecycle management strategies of inno-
vative oncology immunotherapies, specifically the PD-1 drugs pembrolizumab 
(Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb), for application 
across disease areas. Methods: Targeted secondary research using combina-
tions of key words (‘PD-1’, ‘Keytruda’, ‘Opdivo’, ‘FDA’, ‘Pembrolizumab’, ‘Nivolumab’, 
‘Approval’, ‘Immuno-oncology’) identified source literature, which was abstracted 
and analyzed qualitatively. Key themes were discussed in a consensus meeting and 
implications of findings were theorized. Results: Several lifecycle management 
strategies were identified from secondary research, including: indication expansion, 
patient segmentation using biomarkers, and combining with other drug treatments. 
Pembrolizumab and nivolumab - both holders of Breakthrough Therapy status - 
received accelerated approval from the FDA for advanced melanoma in late 2014. 
Nivolumab subsequently received approval for NSCLC in March 2015, while pem-
brolizumab was under FDA Priority Review for the same indication as of June 2015. 
Nivolumab is also under Priority Review in combination with ipilimumab (Yervoy, 
Bristol-Myers Squibb) for melanoma. Both PD-1 therapies are in numerous clinical 
trials for further oncology indications, and pembrolizumab has shown improved 
response rates in patients with a specific genetic biomarker, which is predictive of 
response across a range of cancers. ConClusions: In highly competitive therapeu-
tic areas, manufacturers of innovative products need to consider multiple strategies 
for creating, maintaining, protecting and increasing product value. Demonstration of 
substantial improvements in clinical efficacy over the standard of care in one indi-
cation is not sufficient for ‘success’. Earlier access through the FDA’s Breakthrough 
Therapy designation and accelerated approval program is critical for first-to-market 
entrants. Expansion into both larger and more niche indications offers a comple-
mentary access strategy, while gaining a foothold in combination regimens pro-
vides opportunity for further product differentiation. Similar considerations apply 
to therapies that can treat several indications within a broader disease area.
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objeCtives: Observational studies can be useful to fill in gaps of randomized stud-
ies or when these cannot be conducted. Aim of this study was the assessment of 
available real world evidence (RWE) in oncology and the identification of research 
gaps for Germany. Methods: A systematic literature search was conducted to 
evaluate the status quo of RWE in the field of oncology. Key words identifying 
health services research in combination with oncology in Germany were used in 
a search performed in the DIMDI (German Institute of Medical Documentation 
and Information) meta-database including all years up to 2015. The selected pub-
lications were classified by type of RWE study and further categorized by cancer 
types. Results: In total, 80 publications were included and stratified by RWE 
approach and cancer type. Nine RWE categories were determined, including cancer 
registries, registry-linked data, health care claims, inpatient and outpatient data, 
and surveys. Most observational studies (56%) assessed oncologic health care by 
conducting surveys, followed by cancer registries (10%) and claims data (9%). Overall, 
32 studies evaluated cancer in general, breast cancer was assessed in 15 studies, 
whereas 4 addressed prostate cancer, with remaining publications addressing other 
cancer types. Most observational studies were published in 2011 (18%). Assessments 
with cancer registries were published as of 2011, whereas there were no studies 
with claims data from 2012-2014. Specific care and treatment of cancer patients, 
including palliative care was considered in 23 publications. Almost all cancer types 
were assessed, except lymphoid and hematopoietic neoplasms. Moreover, claims 
data were hardly used. For surveys, it can be noted that the use increased from 2005 
onwards. ConClusions: The available evidence shows that RWE data in oncology 
has not yet reached its potential to supplement randomized studies. Research gaps 
exist in terms of RWE treatment with new concepts and drugs.
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objeCtives: Breast cancer has important economic, psychological and social 
impact for the patients, their families and the health system. Our aim was to 
record the emotional journey of patients with breast cancer during the different 
treatment stages. Methods: A qualitative study was performed in December 
2014, using a semi-structured interview guide. Participants were recruited through 
a patients’ organization. Women with a diagnosis of primary or secondary breast 
Ca after 2011, residing in Athens who had completed treatment were eligible 
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objeCtives: To understand how 11 pricing & reimbursement (P&R) processes 
assess the value of innovative medicines to provide sustainable and timely 
patient access. bACkgRound: In November 2014, the UK Minister for Life 
Sciences announced the Innovative Medicines and Medical Technology Review 
to consult various stakeholders on how to improve access to medicines in 
England. Methods: Eleven processes were analysed focusing on oncology: 
Australia, Belgium, Canada, England, France, Germany, Italy, Netherlands, New 
Zealand, Scotland and Sweden. The decision-making process was split into eight 
steps: regulatory approval, health technology assessment, appraisal, reimburse-
ment decision, price negotiations, decision enforcement, routine access and 
later-stage reassessments. Data collection was based on the Hutton and Allen 
frameworks [Hutton et al. 2006] [Allen et al. 2013]. The analysis relies on a pro-
posed definition of patient-centricity, assuming that value creation for patients 
should determine the reward of other stakeholders [Porter 2010]. It was designed 
to assess how each process delivers value for patients (equity of access, fulfil-
ment of societal needs, fast access to innovation), the healthcare system (eco-
nomic and financial sustainability) and the research-based industry (innovation 
reward). Results: In patient-centric systems, the reimbursement decision tends 
to be solely based on the therapeutic value of the medicine. Cost considerations 
are generally addressed by price negotiations in a second stage. Other processes 
focus more on cost-effectiveness or budget impact (potentially with thresholds), 
which drives the reimbursement decision alongside clinical effectiveness; pricing 
and reimbursement are decided jointly. The English and Scottish processes are the 
only ones that have no price negotiations with manufacturers. ConClusions: 
Patient-centric P&R processes succeed in delivering value to major stakeholders 
by first deciding on the reimbursement status of a new medicine based on its 
value to patients. They then independently negotiate a price with manufacturers 
to ensure economic and financial sustainability for the healthcare system and 
innovation reward for the manufacturer.
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objeCtives: Research findings point to the existence of delays in symptom rec-
ognition, diagnosis and treatment of breast cancer. The present study aimed at 
identifying reasons for delay in breast cancer diagnosis in Greece. Methods: 
A qualitative study was performed in December 2014, using a semi-structured 
interview guide. Recruitment was performed through a patients’ organization. 
Women with a diagnosis of primary or secondary breast Ca after 2011, residing 
in Athens, and who had completed treatment were eligible for the study. The 
interviews were recorded with participants’ written consent and were transcribed 
and content analyzed using a model of patient and provider delay. Results: 23 
women participated. Delays were detected in all intervals of the patient pathway. 
Although most participants performed annual breast cancer screening tests, some 
women had not undergone screening the year previous to their diagnosis due to 
financial and personal reasons. In the majority of cases women were symptomatic, 
however, there were difficulties in appraising symptoms as related to illness. The 
presence of a breast lump is the main symptom that caused non-delayers to seek 
medical attention. Women who had delayed consulting with a physician despite 
having found a breast lump gave the following reasons: misattributing their symp-
tom to benign conditions or breast-feeding, having competing priorities such as 
family and other personal health problems, depression or denial and financial 
barriers to visiting a specialist. The study also identified delays in diagnosis attrib-
uted to the healthcare providers, as in some cases physician(s) did not suspect 
malignancy. ConClusions: Delayed diagnosis of breast cancer among women 
participating in the study is attributed to both patient and provider behavior. Our 
findings indicate that raising awareness and educating both patients and health 
providers is important. However, further research is necessary to identify the 
extent of the problem and confirm these results.
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objeCtives: Real-world evidence (RWE) can be gathered from various sources, 
including existing registries, claims data or medical records. The challenge is select-
ing the best RWE-source for answering specific research questions. As data sources 
collect different data elements, the best RWE collection approach for gathering 
the necessary data will differ per country. The objective was to test a systematic 
approach for identifying and selecting RWE-sources per indication. Methods: 
Our approach consisted of two workstreams: assessment of existing RWE-sources 
and inventory of data elements collected in clinical practice. We selected oncol-
ogy as test indication and the European Union as the target area. The first step of 
workstream one is a targeted literature search to identify RWE-sources. Database 
owners were surveyed on their data. A scoring algorithm was developed to prioritize 
RWE-sources on the number and type of relevant data elements. Finally, the most 
promising databases for answering specific research questions were selected based 
on their score and collaboration possibilities. For workstream two, a small sample 
of practicing physicians were interviewed on what data is routinely recorded in 
clinical practice. The results from the two workstreams were combined to analyse 
per country which collection approach is optimal for RWE generation for answering 
